Australia markets closed

Almirall, S.A. (ALM.MC)

MCE - MCE Delayed price. Currency in EUR
Add to watchlist
9.85+0.02 (+0.25%)
At close: 05:35PM CEST
Full screen
Previous close9.83
Open9.80
Bid9.83 x 0
Ask9.85 x 0
Day's range9.71 - 9.86
52-week range7.16 - 10.08
Volume169,584
Avg. volume180,993
Market cap2.102B
Beta (5Y monthly)0.38
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.18 (1.87%)
Ex-dividend date17 May 2024
1y target estN/A
  • Investing.com

    Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent

    Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).